目的 探討左旋咪唑聯(lián)合羥氯喹治療系統(tǒng)性紅斑狼瘡的臨床療效。方法 選取2013年2月-2016年2月在廣西壯族自治區(qū)南溪山醫(yī)院治療的系統(tǒng)性紅斑狼瘡患者70例，根據(jù)治療方法的差別分為對照組（35例）和治療組（35例）。對照組患者口服硫酸羥氯喹片，200 mg/次，2次/d。治療組在對照組基礎(chǔ)上口服鹽酸左旋咪唑片，50 mg/次，2次/d。兩組患者均治療6個(gè)月。評價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者血清炎性因子、血清補(bǔ)體和β₂-微球蛋白（β₂-MG）水平以及SLEDAI評分。結(jié)果 治療后，對照組和治療組患者的總有效率分別為80.00%、97.14%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清IL-4、IL-6及IFN-γ水平均顯著降低，IL-2水平明顯升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述血清炎性因子指標(biāo)明顯優(yōu)于對照組（P<0.05）。治療后，兩組患者血清C1q、C3、C4水平明顯增加，β₂-MG水平明顯降低，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組上述補(bǔ)體和β₂-MG水平顯著優(yōu)于對照組患者（P<0.05）。治療后，兩組患者SLEDAI評分明顯降低（P<0.05）；且治療組SLEDAI評分比對照組更低（P<0.05）。結(jié)論 左旋咪唑聯(lián)合羥氯喹治療系統(tǒng)性紅斑狼瘡具有較好的臨床療效，可有效改善患者臨床癥狀和血清學(xué)指標(biāo)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of levamisole combined with hydroxychloroquine in treatment of systemic lupus erythematosus. Methods Patients (70 cases) with systemic lupus erythematosus in Nanxishan Hospital of Guangxi Zhuang Autonomous Region from February 2013 to February 2016 were divided into control (35 cases) and treatment (35 cases) groups according to different treatment. Patients in the control group were po administered with Hydroxychloroquine Sulfate Tablets, 200 mg/time, twice daily. Patients in the treatment group were po administered with Levamisole Hydrochloride Tablets on the basis of the control group, 50 mg/time, twice daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacy was evaluated, and the serum inflammatory factors, serum levels of complement and β₂-MG, and SLEDAI score in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.00% and 97.14%, respectively, and there were differences between two groups (P<0.05). After treatment, the IL-4, IL-6 and IFN-γ level in two groups was significantly decreased, but IL-2 level was significantly increased, and there were differences in the same group (P<0.05). And these serum inflammatory factors in the treatment group were obviously better than those the control group (P<0.05). After treatment, the C1q, C3 and C4 level in two groups was significantly increased, but β₂-MG level was significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum level of complement and β₂-MG in the treatment group was obviously better than that the control group (P<0.05). After treatment, the SLEDAI score in two groups was significantly decreased (P<0.05). And the SLEDAI score in the treatment group was obviously lower than that the control group (P<0.05). Conclusion Levamisole combined with hydroxychloroquine has good clinical curative effect in treatment of systemic lupus erythematosus, can effectively improve the clinical symptoms and serological indicators, which has a certain clinical application value.